Resistance training limits lean-mass loss during tirzepatide treatment, trial finds
A 40-week randomized trial of 120 adults found that resistance training with tirzepatide reduced lean-tissue loss and improved strength. Weight loss stayed similar between groups.
In a 40-week Nature Medicine trial, 120 adults with overweight or obesity taking tirzepatide were assigned to three supervised resistance sessions each week or usual activity. The exercise group lost 3.57 kilograms of lean soft tissue, compared with 4.67 kilograms in the usual-activity group.1
Participants in the exercise group also gained strength in bench press, lat pulldown and knee extension, while the usual-activity group lost strength. Both groups lost about 22 kilograms, with no meaningful difference in weight loss.1
For trainers, the trial added direct evidence that resistance training can limit lean-tissue loss and improve strength during tirzepatide treatment.1
